CJC-1295 / Ipamorelin Research Profile

What Are CJC-1295 & Ipamorelin?

CJC-1295 is a synthetic 29-amino acid analog of growth hormone-releasing hormone (GHRH) engineered with a Drug Affinity Complex (DAC) that enables covalent binding to circulating serum albumin. This bioconjugation technology, developed by ConjuChem Biotechnologies, extends the peptide’s biological half-life from approximately 7 minutes (native GHRH) to 5.8–8.1 days — enabling sustained, dose-dependent growth hormone elevation from a single subcutaneous administration.[1]

Ipamorelin (NNC 26-0161) is a synthetic pentapeptide growth hormone secretagogue that acts as a selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R1a). First characterized by Raun et al. in 1998, ipamorelin was identified as the first growth hormone secretagogue that selectively stimulates GH release without significantly affecting ACTH, cortisol, prolactin, or FSH/LH levels — a selectivity profile that distinguishes it from earlier GHS compounds such as GHRP-6 and GHRP-2.[5]

The two peptides act through complementary receptor pathways: CJC-1295 stimulates pituitary GH release via the GHRH receptor, while ipamorelin amplifies the signal through the ghrelin receptor. This dual-receptor approach has driven research interest in the combination as a means of producing synergistic GH elevation while preserving the pulsatile secretion pattern that maintains physiological feedback regulation.[11]

Neither CJC-1295 nor ipamorelin has been approved by the FDA for therapeutic use. Both are classified as research compounds. All information presented here reflects findings from published preclinical and early-phase clinical studies.

Mechanism of Action

CJC-1295 and ipamorelin stimulate growth hormone secretion through distinct but synergistic receptor-mediated pathways:[2]

• CJC-1295 — GHRH Receptor Agonism: CJC-1295 binds to GHRH receptors (GHRHR) on anterior pituitary somatotrophs, activating the cAMP/PKA signaling cascade that stimulates GH gene transcription and secretion. The DAC modification enables albumin bioconjugation, dramatically extending circulating half-life while preserving receptor binding affinity.[2]
• Ipamorelin — GHS-R1a Agonism: Ipamorelin binds to ghrelin receptors (GHS-R1a) on pituitary somatotrophs, stimulating GH release through a PLC/IP3/calcium signaling pathway distinct from the GHRH pathway. Its selectivity for GH over ACTH and cortisol is attributed to its specific binding profile at the GHS-R1a receptor.[5]
• Preserved Pulsatility: Clinical data demonstrates that CJC-1295 increases GH secretion while preserving the endogenous pulsatile pattern rather than producing tonic elevation. This characteristic may be significant for maintaining hypothalamic-pituitary feedback regulation.[16]
• IGF-I Axis Stimulation: Both compounds increase hepatic IGF-I production as a downstream consequence of GH elevation. CJC-1295 has been shown to produce sustained IGF-I elevation lasting 9–11 days following a single injection, suggesting prolonged somatotropic axis activation.[1]
• Bone Metabolism Effects: Ipamorelin has demonstrated direct effects on bone growth through GH-mediated pathways, with studies reporting dose-dependent increases in longitudinal bone growth rate independent of other endocrine axes.[6]

Key Research Findings

GH Axis & Pharmacokinetics

The pharmacokinetics of CJC-1295 were first characterized by Jetté et al. (2005), who identified the compound through a systematic screen of human growth hormone-releasing factor (hGRF) albumin bioconjugates. The key innovation was the reactive glutamine at position 8 enabling site-specific covalent attachment to Lys34 of serum albumin, transforming a rapidly cleared peptide into a long-acting therapeutic analog.[2]

Teichman et al. (2006) conducted the pivotal clinical pharmacology study in healthy adults, demonstrating that single subcutaneous CJC-1295 injections at doses of 30, 60, and 125 μg/kg produced dose-dependent GH elevations sustained for over 6 days, with IGF-I increases persisting 9–11 days. Multiple-dose regimens produced 1.5- to 3-fold increases in mean GH concentrations with preserved pulsatile patterns.[1]

Importantly, Ionescu et al. (2006) demonstrated that CJC-1295 stimulation preserved the pulsatile pattern of GH secretion rather than producing continuous tonic release. This finding is significant because pulsatile GH secretion is considered more physiologically relevant than sustained elevation for maintaining hepatic GH receptor sensitivity and IGF-I signaling.[16]

Alba et al. (2006) provided preclinical validation in a GHRH knockout mouse model, demonstrating that daily CJC-1295 administration normalized growth velocity, body weight gain, and IGF-I levels in mice lacking endogenous GHRH signaling — confirming the compound’s ability to functionally replace endogenous GHRH.[3]

Rasmussen et al. (2011) extended the clinical characterization of GHRH analogs by examining effects on GH pulsatility and insulin sensitivity, reporting augmented basal and pulsatile GH secretion while preserving insulin-stimulated glucose uptake, an important finding for metabolic safety profiling.[17]

Bone Metabolism & Body Composition

Ipamorelin’s effects on bone metabolism represent one of its most extensively studied research areas. Thøgersen et al. (1999) demonstrated that ipamorelin produced dose-dependent increases in longitudinal bone growth rate in rats, with effects on body weight gain that paralleled those of exogenous GH administration. The study established ipamorelin as an effective stimulator of the GH-IGF-I axis with measurable bone growth effects.[6]

Andersen et al. (2001) investigated ipamorelin in a clinically relevant model of glucocorticoid-induced bone loss. The study demonstrated that ipamorelin successfully counteracted the suppressive effects of methylprednisolone on bone formation markers in adult rats, suggesting potential utility in research on steroid-induced osteopenia.[7]

The effects on pituitary function were further characterized by Jiménez-Reina et al. (2002), who examined chronic ipamorelin administration effects on somatotroph cells in young female rats, demonstrating sustained modulation of pituitary GH responsiveness without desensitization.[8]

Aagaard et al. (2009) examined the broader metabolic effects of GH secretagogues including ipamorelin in steroid-treated rats, reporting improved nitrogen balance and reduced urea synthesis — indicating anabolic effects on protein metabolism that extend beyond bone-specific outcomes.[9]

Sinha et al. (2020) published a comprehensive review examining GH secretagogues including the CJC-1295/ipamorelin combination in the context of body composition management in hypogonadal males, synthesizing evidence for effects on lean mass, fat mass, and metabolic parameters.[11]

GI Motility & Emerging Research

Ipamorelin’s activity at the ghrelin receptor has opened a distinct research avenue beyond growth hormone stimulation. Venkova et al. (2009) demonstrated that ipamorelin, functioning as a ghrelin mimetic, accelerated gastrointestinal transit and ameliorated symptoms in a rodent model of postoperative ileus — a common and clinically significant complication following abdominal surgery.[10]

Lu et al. (2024) further explored the GI applications of ghrelin receptor agonists, demonstrating that both ipamorelin and anamorelin inhibited cisplatin-induced weight loss and reduced feeding inhibition in a ferret model, with anamorelin additionally demonstrating central anti-emetic effects. These findings support research into GHS-R1a agonists for chemotherapy-associated cachexia and anorexia.[12]

A 2024 review in Reviews in Endocrine and Metabolic Disorders synthesized the broader therapeutic landscape of GHRH analogs and GH secretagogues, examining emerging applications in regenerative medicine, wound healing, cancer research, and metabolic disorders. The review highlighted the expanding scope of investigation beyond classical GH replacement paradigms.[18]

Analytical detection methodologies have advanced alongside the research literature. Henninge et al. (2010) developed identification protocols for CJC-1295 in pharmaceutical preparations, while Timms et al. (2019) established LC-MS/MS confirmation methods for CJC-1295 in equine plasma, and Memdouh et al. (2021) reviewed comprehensive detection strategies for GHRH synthetic analogs — collectively advancing the forensic and analytical characterization of these compounds.[4][13][15]

Summary of Research

CJC-1295 and ipamorelin represent two of the most extensively characterized compounds in growth hormone secretagogue research. The published literature supports several key research themes:

• GH Axis Pharmacology: CJC-1295 produces sustained, dose-dependent GH and IGF-I elevation with preserved pulsatility, while ipamorelin provides selective GH secretion without cortisol or prolactin effects.[1][5]
• Bone Metabolism: Ipamorelin demonstrates dose-dependent effects on longitudinal bone growth and counteracts glucocorticoid-induced bone loss in preclinical models.[6][7]
• Body Composition: The combination has been reviewed for effects on lean mass, fat mass, and nitrogen balance in catabolic and hypogonadal states.[9][11]
• GI Motility: Ipamorelin’s ghrelin receptor activity has demonstrated efficacy in postoperative ileus and chemotherapy-induced cachexia models.[10][12]

While preclinical and early clinical evidence is substantial, neither compound has been approved for therapeutic use by any regulatory agency. Ongoing research continues to explore the translational potential of dual GHRH-receptor/GHS-receptor stimulation approaches.

Frequently Asked Questions

Citations